Curated News
By: NewsRamp Editorial Staff
June 06, 2025

ABVC's Oncology Licensing Deal with OncoX Highlights Scalable Royalty Strategy

Reddit Discuss on LinkedIn Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • ABVC BioPharma's licensing deal with OncoX could yield up to $105 million, showcasing a strategic move to capitalize on the booming oncology market.
  • ABVC's affiliate OncoX acquires Lycogen® platform for $4.06 million, aiming to develop oncology treatments with a projected $25-30 million revenue over five years.
  • The acquisition of Lycogen® by OncoX, under ABVC's strategy, promises advancements in oncology treatments, potentially improving patient outcomes worldwide.
  • Lycogen®, a next-gen lycopene-analog, joins OncoX's pipeline, highlighting ABVC's innovative approach to leveraging natural compounds for cancer therapy.

Impact - Why it Matters

This news is significant as it showcases ABVC BioPharma's innovative approach to generating non-dilutive revenue through strategic licensing and affiliate partnerships. The acquisition of the Lycogen® platform by OncoX not only expands ABVC's oncology portfolio but also positions the company to capitalize on the growing global demand for natural compound-based therapies. With the oncology drug market expected to reach $484 billion by 2032, this deal could have far-reaching implications for the treatment of cancer and metabolic diseases, offering new hope for patients and creating value for shareholders.

Summary

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced a significant licensing deal with its affiliate, OncoX BioPharma Inc., for the acquisition of the Lycopenoid Lycogen® platform. This deal, valued at approximately USD $4.06 million, includes patented manufacturing technology and commercialization rights from Asia-Pacific Biotech Developing Inc. (APBDI). The Lycogen® platform, known for its next-generation lycopene-analog produced by microbial fermentation, has shown promise in preclinical cancer-related and metabolic disease models due to its antioxidant and anti-inflammatory properties.

The strategic royalty structure of this deal is expected to benefit ABVC significantly, with OncoX forecasting cumulative revenues of USD $25–30 million over the next five years from dermatology, oncology, and nutraceutical sectors. ABVC's CEO, Dr. Uttam Patil, highlighted the transaction as a milestone in the company's strategy to monetize platform assets through affiliate-driven development. This move not only strengthens OncoX's commercialization capabilities but also underscores ABVC's commitment to leveraging botanical oncology innovation for growth. The global oncology drug market's projected growth to $484 billion by 2032 and the increasing demand for natural compounds like lycopene underscore the potential impact of this deal.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, ABVC's Oncology Licensing Deal with OncoX Highlights Scalable Royalty Strategy

blockchain registration record for this content.